New drug targets Hard-to-Treat cancers with RAS mutations
NCT ID NCT06884618
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called RO7673396, alone or with other cancer treatments, in people with advanced solid tumors that have RAS mutations. The study has two parts: first to find a safe dose, then to see if it shrinks tumors. About 405 participants will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RO7673396
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have RAS mutations.
What could go wrong
This is a very early Phase 1 trial, so the drug may not be effective or safe. It is small and focused on finding the right dose, not on proving it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Comprehensive Cancer Center
RECRUITINGDuarte, California, 91010, United States
-
Clinica Universidad de Navarra
RECRUITINGPamplona, Navarre, 31008, Spain
-
Florida Cancer Specialists - Sarasota (North Catttlemen Rd)
RECRUITINGSarasota, Florida, 34232, United States
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 201315, China
-
Hubei Cancer Hospital
RECRUITINGWuhan, 430079, China
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-3721, United States
-
National Cancer Centre - 30 Hospital Blvd
RECRUITINGSingapore, 168583, Singapore
-
National Cheng Kung University Hospital
RECRUITINGTainan, 70403, Taiwan
-
National Taiwan University Hospital
RECRUITINGTaipei, 10002, Taiwan
-
New Zealand Clinical Research - Auckland
RECRUITINGAuckland, 1010, New Zealand
-
New Zealand Clinical Research - Christchurch
RECRUITINGChristchurch, 8011, New Zealand
-
Peter MacCallum Cancer Center
RECRUITINGParkville, Victoria, 3052, Australia
-
Prince of Wales Hospital
RECRUITINGHong Kong, Hong Kong
-
Princess Margaret Hospital
RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Rigshospitalet
RECRUITINGKøbenhavn Ø, 2100, Denmark
-
Smilow Cancer Hospital at Yale New Haven
RECRUITINGNew Haven, Connecticut, 06519-1110, United States
-
South Texas Accelerated Research Therapeutics (START)
RECRUITINGSan Antonio, Texas, 78229-4427, United States
-
St Vincent's Hospital Sydney
RECRUITINGDarlinghurst, New South Wales, 2010, Australia
-
Sun Yat-Sen University Cancer Center - Huangpu Campus
RECRUITINGGuangzhou, Guangdong, 510555, China
-
Sun Yat-Sen University Cancer Center;Department of Thoracic Surgery
RECRUITINGGuangzhou, 510050, China
-
University of Colorado - Anschutz Medical Campus - PPDS
RECRUITINGAurora, Colorado, 80045, United States